A device developed through more than a decade of research in Łódź has produced encouraging results in a controlled clinical trial involving people with early Alzheimer’s disease.
The Vguard system delivers gentle electrical stimulation to the vagus nerve through electrodes placed around the ear while a patient sleeps. In a randomised, double-blind trial, participants receiving active stimulation showed statistically significant improvements in cognitive performance compared with a sham-treatment group.
The findings have now been published in the Journal of Alzheimer’s Disease, bringing a Polish-developed approach to one of medicine’s most difficult neurological conditions into the peer-reviewed scientific literature.
- Find more news from Poland on our Homepage .
It is an encouraging result, but not a cure for Alzheimer’s disease. The study was relatively small, and further research will be needed to establish how durable the effect is, which patients may benefit most and how the approach compares with existing treatments.
Using sleep as part of the treatment
Vguard uses a technique known as auricular transcutaneous vagus nerve stimulation. Unlike implanted vagus-nerve stimulators, it does not require surgery.
The device is worn as a headband, with electrodes positioned in the outer ear. Electrical impulses are delivered during sleep, when vagal activity is naturally higher and the brain is involved in consolidating memories.
Researchers assessed participants using four established neuropsychological tests, including the Alzheimer’s Disease Assessment Scale Cognitive Subscale, or ADAS-Cog, one of the standard tools used to measure cognitive change in Alzheimer’s research.
Earlier reporting of the same clinical programme describes 51 participants, with 35 assigned to active treatment and 16 to a sham-stimulation control group during an initial 12-week period. Twenty participants continued into a further 12-week extension.
The strongest difference between the treatment and control groups was recorded on ADAS-Cog, with researchers also reporting improvements on other tests of memory and cognitive performance.
Fresh Polish reporting on the study says measurable changes were already apparent after the first month of treatment and that no serious side effects were recorded during the trials.
One detail also underlines why the results should be treated cautiously rather than presented as evidence of a permanent recovery. Among 15 participants assessed after stimulation had been stopped for a further 24 weeks, the cognitive improvement returned to baseline levels.
That suggests the intervention may support cognitive function while being used, but the study does not show that it permanently reverses Alzheimer’s disease.
More than a decade of research in Łódź
The project grew from work on how stimulation of the vagus nerve influences brain regions involved in learning and memory.
Researchers at the University of Łódź’s Department of Neurobiology carried out preclinical work that helped establish the scientific basis for the technology. Their experiments found that vagus-nerve stimulation could induce theta activity in the hippocampus — a brain region central to memory formation.
That research helped shape the clinical protocols and stimulation parameters later used in Vguard.
The published clinical paper was led by Łódź neurologist Adam Broncel and includes researchers affiliated with Neuromedical in Łódź, the Medical University of Łódź and the University of Gothenburg in Sweden.
The Journal of Alzheimer’s Disease article was first published online on 9 June and appeared in the journal’s August issue. It describes nocturnal vagus-nerve stimulation as a potentially promising approach for improving cognition in people with mild cognitive impairment and early Alzheimer’s disease.
The technology has also moved beyond laboratory development. Earlier this year, Vguard won the 4CLIENT category of the EEC Startup Challenge in Katowice, with the University of Łódź highlighting the role its researchers played in the device’s development.
What makes the latest result significant is not that Alzheimer’s disease has suddenly been solved. It has not.
Rather, years of neurological research in Łódź have progressed from experiments on the mechanisms of memory to a non-invasive device tested in a randomised, double-blind human study — with measurable cognitive effects strong enough to warrant further investigation.
